24.7. Elimination of urine studies when screening for monoclonal gammopathies

Chapter 24

A number of studies have now been published identifying the benefit of including sFLC analysis in screening protocols for lymphoproliferative disorders. In addition, two large diagnostic studies from the Mayo clinic [521][522] led to the conclusion that urine analysis could be eliminated, unless AL amyloidosis was suspected. These data are presented and discussed in Chapter 23 and the conclusions are now reflected in the IMWG guidelines (Chapter 25).